What sector does Senores Pharmaceuticals L belong to?

Senores Pharmaceuticals L operates in the Healthcare sector, specifically the Pharmaceuticals industry, and is listed on the NSE.

What is the current share price of SENORES?

As of the latest available quote, SENORES traded at ₹1,467.30. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of SENORES?

Senores Pharmaceuticals L has a price-to-earnings (P/E) ratio of about 51.81. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of SENORES?

The market capitalisation of Senores Pharmaceuticals L is approximately ₹6,757 Cr.

Is Senores Pharmaceuticals L profitable?

For its latest reported financial year, Senores Pharmaceuticals L recorded a net profit margin of about 19.27%.

Does SENORES pay a dividend?

Senores Pharmaceuticals L does not currently show a dividend yield in our data.

What is the return on equity (ROE) of SENORES?

Senores Pharmaceuticals L has a return on equity (ROE) of about 13.40%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of SENORES?

Over the past 52 weeks, SENORES has traded between a low of ₹662.45 and a high of ₹1,599.00.

Senores Pharmaceuticals L

SENORES NSE Healthcare Pharmaceuticals

₹1,467.30

+0.29%

Delayed · cached 15 min

Fair value analysis

SENORES

Senores Pharmaceuticals L

₹1,463.10

Close used for this calculation

₹661.97Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

43/100

Profitability23/25

Returns5/25

Balance Sheet9/25

Efficiency6/25

Growth12/25

Average

Quality radar

Consensus fair value

₹661.97

Above FV

▼ -54.8% against the close used

Model range ₹353.48 – ₹1,128.14

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹353.48Fair value₹661.97Bull₹1,128.14

FairClose

52-week traded range

52W low ₹673.6052W high ₹1,550.90

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Senores Pharmaceuticals L closed at ₹1,463.10, 121.0% above the consensus fair value of ₹661.97 drawn from 9 valuation models.

Financial DNA score 43/100 — Average. P/E of 53.5x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

₹497.22

-66.0%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

Graham Number

₹353.48

-75.8%

√(22.5 × EPS × BVPS)

EPS=25.05, BVPS=221.68 · outside Graham range (P/E 53.5, P/B 6.6) — asset-light, treat as a rough floor

Graham Formula

₹1,128.14

-22.9%

EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate

g=20%, FD=7%

P/E Fair Value

₹894.29

-38.9%

EPS × 35.7x (sector P/E)

EPS=25.05, Sector P/E=35.7x

Peter Lynch (PEG)

₹626.25

-57.2%

EPS × Growth% (PEG = 1 is fair)

EPS=25.05, g=25%

EV/EBITDA

₹701.56

-52.0%

(EBITDA × 18x − Net Debt) ÷ Shares

EBITDA=1.99B

Book Value (P/B)

₹410.11

-72.0%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=221.68, ROE=13.4%, g=6%, r=10%

Reverse DCF

₹1,463.10

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 21.7% | Historical: 25%

Margin of Safety

₹538.71

-63.2%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=718.28, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer